crizotinib - Wyniki wyszukiwania

Unia Europejska - polski - EMA (European Medicines Agency)

xalkori

pfizer europe ma eeig - kryzotynib - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Unia Europejska - polski - EMA (European Medicines Agency)

alecensa

roche registration gmbh - chlorowodorek alektynibu - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - alecensa jako monoterapia jest wskazana w leczeniu pierwszego rzutu u dorosłych pacjentów z niedrobnokomórkowym rakiem płuca (nsclc) z niedrobnokomórkowym rakiem komórkowym (alk). alecensa w monoterapii jest przeznaczony do leczenia dorosłych pacjentów z alk‑dodatnim nsclc, wcześniej leczonych crizotinib.

Unia Europejska - polski - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Unia Europejska - polski - EMA (European Medicines Agency)

lorviqua

pfizer europe ma eeig - lorlatinib - rak, niedrobnokomórkowe płuca - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.